ASH — Ashland Inc.

Summary of Ashland (ASH) Q3 2026 Earnings Call

1. Key Financial Results and Metrics

• Sales: $497 million, up 7% year-over-year, driven by volume growth across all business units.
• Volume Growth: Increased 6% across the portfolio, with notable strength in Life Sciences and Personal Care.
• Adjusted EBITDA: $109 million, down from $113 million in the prior year; Adjusted EBITDA margin at 21.9%, compared to 24.4% year-over-year.
• Adjusted EPS: $1.20, down from $1.40 in the prior year.
• Free Cash Flow: $103 million, with a conversion rate above 90%.
• Net Leverage: 2.4x, returning to long-term target range.

2. Strategic Updates and Business Highlights

• Life Sciences: Achieved 11% sales growth, driven by strong demand in pharma, particularly high purity excipients and injectables. Continued momentum from Globalize and Innovate strategies.
• Personal Care: Sales increased 5%, with strong performance in biofunctional actives and skincare. New microbial protection facility in Europe opened.
• Specialty Additives: Sales up 4%, driven by share gains in coatings and performance specialties despite mixed demand conditions.
• Intermediates: Sales increased 12%, supported by higher demand for NMP in EV battery applications.
• Manufacturing Optimization: Progress noted in operational performance, with ongoing initiatives expected to yield structural savings of approximately $15 million this fiscal year.

3. Forward Guidance and Outlook

• Fiscal 2026 Guidance: Sales expected between $1.835 billion and $1.870 billion; adjusted EBITDA forecasted at $385 million to $400 million. Adjusted EPS outlook revised to low- to mid-single-digit growth due to a higher tax rate.
• Q4 Expectations: Anticipated further profitability improvement, with pricing actions gaining traction and operational performance gradually improving.

4. Bad News, Challenges, or Points of Concern

• Profitability Impact: Lower production rates earlier in the fiscal year affected profitability; production challenges at the Hopewell facility remain a concern.
• Adjusted EBITDA Decline: Year-over-year decline in adjusted EBITDA reflects challenges in specialty additives and intermediates.
• Market Conditions: Mixed demand in construction and energy resources continues to pose challenges, particularly in the Specialty Additives segment.
• Operational Headwinds: Ongoing issues with manufacturing optimization and production rates could impact future performance.

5. Notable Q&A Insights

• Pricing Strategy: Management indicated that pricing actions are expected to continue improving, with a focus on recovering inflation without expanding margins.
• Manufacturing Optimization: Progress is being made, but full benefits may take time to materialize. The company is cautious about promising rapid improvements.
• Life Sciences Growth: Strong demand in pharma, particularly related to GLP-1 drugs, is expected to sustain future growth.
• Customer Engagement: Positive feedback from customers regarding innovation platforms, with potential for future collaborations and joint ventures.
• Board Changes: Recent cooperation agreement with Ancora includes the addition of two independent directors to enhance governance and strategic oversight.

Overall, Ashland reported solid growth across its business segments, with strategic initiatives yielding positive results. However, challenges in production and market conditions remain areas of focus as the company looks to improve profitability and operational efficiency moving forward.